Drug Profile
Research programme: CNS therapeutics - Plex Pharmaceuticals
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Plex Pharmaceuticals
- Class Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors; Tumour necrosis factor receptor-associated peptide and protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Glioblastoma; Parkinson's disease
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
- 28 Feb 2020 No recent reports of development identified for research development in Glioblastoma in USA
- 28 Feb 2020 No recent reports of development identified for research development in Parkinson's-disease in USA